Dr. Saloura is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 N. Broadway
Baltimore, MD 21287
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2011 - 2014
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 2008 - 2011
University of AthensClass of 2004
Certifications & Licensure
MD State Medical License 2020 - 2025
IL State Medical License 2011 - 2020
PA State Medical License 2008 - 2011
Clinical Trials
- Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS Start of enrollment: 2024 Jun 26
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models.Daniel E Tsai, Alexei Lovanov, Abdalla Abdelmaksoud, Jawad Akhtar, Mohd Saleem Dar
Iscience. 2024-09-20 - 3 citationsIntegrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.Hidenori Machino, Ai Dozen, Mariko Konaka, Masaaki Komatsu, Kohei Nakamura
Experimental & Molecular Medicine. 2023-10-01 - 3 citationsA multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.A J Rosenberg, C-Y Liao, T Karrison, J A de Souza, F P Worden
Annals of Oncology. 2023-08-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
